Text size :

Tumors: breast cancer, Aiom ‘patients still poorly informed about precision oncology’ (2)

ADNKRONOS

November 15, 2026

(Adnkronos Health) – “Diagnostic systems have undergone a remarkable evolution over the last 15 years, hand in hand with that recorded in drugs – continues Massimo Di Maio, Aiom president -. For example, the new-generation gene sequencing test Ngs allows us to identify the specific genetic mutations that drive tumor growth. It is among the most complete and precise tests available so far and is capable of analyzing a large number of gene mutations. Some panels include dozens of genes, others even hundreds. This type of analysis does not necessarily have to be performed in the same center that clinically follows the patient, and the samples to be analyzed can also travel from one center to another. The necessary tests, in order to decide the best therapeutic strategy in clinical practice, must in any case be guaranteed to patients promptly.”

“Liquid biopsy represents one of the most innovative tools in precision oncology because it allows identifying, through a simple blood sample, molecular alterations that can guide therapeutic choices, making treatments increasingly personalized – states Rossana Berardi, Aiom president-elect -. In advanced breast carcinoma, for example, Esr1 gene mutations can be found in up to 40% of Hr+/Her2- cases previously treated with endocrine therapy and represent an important mechanism of resistance to hormonal treatments. Their timely identification now allows selecting patients who can benefit from new targeted therapies, expanding treatment opportunities. The added value of liquid biopsy also lies in its minimal invasiveness and the possibility of monitoring the molecular evolution of the disease over time, adapting therapeutic strategies to the tumor’s characteristics and the needs of the individual patient.”

“The management of breast cancer should be as multidisciplinary as possible, as 86% of respondents rightly maintain – adds Perrone -. ‘Teamwork’ is what guarantees the quality of Breast Units, which should increasingly be supported by the advice of Molecular Tumor Boards. These structures must be entrusted with the task of establishing molecular analysis strategies and subsequently interpreting the results obtained.” “Molecular Tumor Boards represent a fundamental element for the development of precision oncology, but the real challenge is to ensure that these opportunities are accessible to all patients, regardless of the Region or the center where they are treated – concludes Berardi -. This is precisely one of the priorities of the single National Coordination Center for Molecular Tumor Boards, established by the Ministry of Health, of which I have the honor of being a part: to promote homogeneous pathways, diagnostic and therapeutic appropriateness, and equal opportunities for access to innovation throughout the national territory. Alongside scientific and organizational progress, however, it is also essential to strengthen communication with patients. Innovation must not only be available but also understandable and shared, through clear, transparent, and continuous dialogue between specialists and people involved in the care pathway. So that precision medicine can truly become a right for everyone and not an opportunity reserved for a few.”

Jiji Press

Related

Page TOP